Onconomics Lite is a laboratory test that analyses how an individual’s circulating tumour cells (CTCs) respond when exposed to wide range of cytotoxic chemotherapy, targeted therapies and monoclonal antibodies.
By evaluating real-time functional reactions of tumour cells, the test identifies which drugs are most likely to be effective — supporting truly personalized cancer therapy planning.
Targets viable CTCs and assesses their reaction to a defined panel of chemotherapy and targeted agents.
Chemotherapy can be physically and emotionally demanding, and when it fails to work, the experience can be even more disheartening for patients and their families.
To help determine whether a specific monoclonal antibody, chemotherapeutic or targeted agent is likely to be effective for an individual’s cancer, the Onconomics Lite test is used.
Onconomics Lite evaluates the sensitivity of live cancer cells to over 50 chemotherapeutic substances and 60+ targeted drugs, helping clinicians identify the most suitable treatment options for each patient.
The test measures the CTC count in the blood.
While conventional methods predict treatment success based on genetic or histological data, Onconomics Lite directly measures the cellular response to anticancer agents.
This approach captures the functional behaviour of viable tumour cells, providing immediate and clinically relevant insight for therapy selection and monitoring.
It offers an in-depth breakdown of the most suitable and successful treatment options for cancer.
It serves as a guide to the treating physician as to the most effective chemotherapy vs a standard protocol which may not work as well. This is particularly important when 2-3rd line treatments are used and found ineffective.
Oncotrail has undergone rigorous evaluation to ensure high sensitivity and specificity, making it an invaluable tool for diagnostic purposes.
Through high-precision techniques, the test is used to monitor the effectiveness of a particular cancer treatment. This would objectively provide information on how well the treatment is going.
The non-invasive tracking of the cancer status would notify a treating physician whether to adjust current management or stay the course. This would be important to know in almost real-time rather than to find out much later that a treatment doesn't apply to a particular person.
Reserve your 15-minute free one on one discussion
Blood or tissue sample (Tissue for CNS Primary Tumors)
15-25 ml peripheral whole blood. Tissue sample: Minimum 400mg.
Approx. 10-12 business days
21 business days after sample collection
Applicable for all cancer types
A patient-centric revolution in cancer testing and monitoring. We are devoted to providing personalized tests designed with each patient’s unique genetic profile in mind.
RGCC Global Ltd
Suite 1701-02, 17/F, FWD Financial Centre, 308 Des Voeux Road Central, Hong Kong
202312501N
+852 7028 5202
IAS Accreditation Testing Laboratory
ISO 22000: 2018
Nr.: 20101200002689
ISO 22716: 2007
Nr.: 20019220006394
College of American Pathologists
Certificate of Accreditation
CAP#: 9239089
CLIA#: 99D2283882
Accreditation Certificate of Foreign Cell Processor
– Japanese Government
IAS Accreditation Medical Laboratory
ISO 45001: 2018
Nr.: 20152220006395
CLIA ID Number 99D2283882
Certificate of GMP Compliance
No. 512863-102689104
Production License for Investigational ATMPs for Human Use
Ref. No. 7282
©2025 Copy Right
